Tumor lysis syndrome following single-dose mitoxantrone.
We report here a 16-year-old boy with pre-B-type acute lymphoblastic leukemia who developed acute tumor lysis syndrome (TLS) following 12 h mitoxantrone infusion. TLS is a distinct clinical entity which has been recognized most frequently with aggressive combination chemotherapy of rapidly proliferating hematologic neoplasms. There have been a few reports of single-agent-induced tumor lysis, but to our knowledge, this is the first case reported with mitoxantrone alone.
Benekli
M
M
Department of Internal Medicine, Hacettepe University, Faculty of Medicine, Ankara, Turkey.
Savaş
M C
MC
Güllü
I H
IH
Kadayifçi
A
A
Akpek
G
G
Kars
A
A
Güler
N
N
Kansu
E
E
Tekuzman
G
G
Firat
D
D
D000293:Adolescent; D000970:Antineoplastic Agents / Q000009:adverse effects*; D006801:Humans; D007770:L-Lactate Dehydrogenase / Q000097:blood; D008297:Male; D008942:Mitoxantrone / Q000009:adverse effects*; D015452:Precursor B-Cell Lymphoblastic Leukemia-Lymphoma / Q000188:drug therapy; D054198:Precursor Cell Lymphoblastic Leukemia-Lymphoma / Q000188:drug therapy; D015275:Tumor Lysis Syndrome / Q000209:etiology*
D000970:Antineoplastic Agents; D008942:Mitoxantrone; D007770:L-Lactate Dehydrogenase